PebbleAtlas
PEBBLE / ATLAS
Open research access
PRECLINICAL PUBLICATION · 2017

The novel mineralocorticoid receptor antagonist finerenone attenuates neointima formation after vascular injury.

Mixed / Other

Evidence by therapy association

Study details and outcomes are extracted in the context of a specific intervention. Separate associations are retained rather than silently merged.

PMID 28926607 ↗2017Reported benefit

The novel mineralocorticoid receptor antagonist finerenone attenuates neointima formation after vascular injury.

MixedOtherC57BL/6 (C57BL/6J)Malen = n = 8 to 9 mice per group for re-endothelialisation; n = 6…Oral gavage, dissolved in 40 per cent macrogol (15)-hydroxystearate and 10 per cent ethanol1 mg/kg/day or 10 mg/kg/day in vivo; 1 nM and 10 nM in vitr…Immediately before surgery, then once daily thereafter

Model: Electric denudation injury of the left common carotid artery (2 W for 2 seconds per millimetre over 4 mm) and wire-induced dilation injury of the femoral artery (0.38 mm straight spring wire advanced 1 cm and left in place for 1 minute)

Finerenone at 10 nM prevented aldosterone-induced smooth muscle cell proliferation and at 1 nM prevented endothelial cell apoptosis in vitro. In vivo, re-endothelialisation at day 3 increased from 0.52 plus or minus 0.12 mm with vehicle to 1.13 plus or minus 0.16 mm at 1 mg/kg/day and 1.083 plus or…

Extraction: extract · Supplied extraction confidence: 0.9. Machine-extracted fields require source verification.